Progress in the studies on small molecule IGF-1R inhibitors.
- Author:
Yan XU
1
;
Guang-shu WANG
;
Wei SUN
;
Xiao-hong YANG
;
Li-bao XU
Author Information
1. Department of Medicinal Chemistry, School of Pharmacy, Jilin University, Changchun 130021, China.
- Publication Type:Journal Article
- MeSH:
Animals;
Apoptosis;
drug effects;
Benzimidazoles;
pharmacology;
Catechin;
analogs & derivatives;
pharmacology;
Cell Line, Tumor;
Humans;
Neoplasms;
pathology;
Piperazines;
pharmacology;
Protein Kinase Inhibitors;
pharmacology;
Pyridones;
pharmacology;
Pyrimidines;
pharmacology;
Pyrroles;
pharmacology;
Receptor, IGF Type 1;
antagonists & inhibitors;
chemistry;
metabolism;
Signal Transduction
- From:
Acta Pharmaceutica Sinica
2008;43(10):979-984
- CountryChina
- Language:Chinese
-
Abstract:
The importance of insulin-like growth factor 1 receptor (IGF-1R) signaling in malignant behaviour of tumour cells is well established. Inhibiting the activity of IGF-1R may result in striking apoptosis in malignant cells growing. IGF-1R antibodies which are currently in phase I and II clinical trials and several IGF-IR TKIs have preclinically been characterized. This review describes recent developments of small molecule tyrosine kinase inhibitors.
